Global Policy on Interactions with Healthcare Professionals



Similar documents
Eucomed. Code of Ethical Business Practice. Eucomed Guidelines on Interactions with Healthcare Professionals

CONDUCTING BUSINESS WITH HEALTH CARE PROFESSIONALS.

MA Healthcare Reform Legislation: Assessment of Massachusetts Department of Public Health Regulations

PhRMA Code on Interactions with Healthcare Professionals

Business Conduct Standards for Interactions with Healthcare Professionals. Pocket Guide for U.S. Sales Professionals. Do The Right Thing

Bayer HealthCare s Comprehensive Compliance Program Pursuant to California Health and Safety Code

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

U.S. PHARMACEUTICALS COMPLIANCE AND ETHICS CODE OF CONDUCT

University of Central Florida College of Medicine Industry Relations Policy and Guidelines. Table of Contents

Code on Interactions with Healthcare. Professionals

Effective March 23, 2015

SUCAMPO PHARMA AMERICAS, LLC COMPREHENSIVE COMPLIANCE PROGRAM

Keeping our Focus: Compliance Summary for Customers and Health Care Professionals. Understanding the Olympus Health Care Compliance Code of Conduct

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire

List of Guiding Principles Promoting Good Governance in the Pharmaceutical Sector 1

EMORY UNIVERSITY SCHOOL OF MEDICINE POLICY ON INDUSTRY AND OTHER EXTERNAL PROFESSIONAL RELATIONSHIPS. Table of Contents

Heraeus Medical Code of Conduct on Interactions with Health Care Professionals

University of Cincinnati College of Medicine

Paul Appelbaum, Julio Arboleda-Flórez, Afzal Javed, Constantin Soldatos, Sam Tyano. WPA Standing Committee on Ethics

Emory Healthcare Policy on Relationships with Vendors, Industry and Other External Professional Relationships

GUIDELINES FOR PHYSICIANS IN INTERACTIONS WITH INDUSTRY

Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009

A PASSION FOR INTEGRITY. Every Day Health Care Compliance. Code of Conduct

Model Code of Ethical Practice for Practitioners of Acupuncture and Oriental Medicine

Advancing research: a physician s guide to clinical trials

CODE OF ETHICS AND CONDUCT

Conflicts of Interest Policy

STATEMENT OF VALUES AND CODE OF ETHICS

The scope of beneficial interactions between Health Care Professionals and Companies is broad and includes interactions intended to:

CODE OF ETHICS AND PROFESSIONAL CONDUCT

Novartis Investigator Initiated Trials (IITs) Guidelines

LIBRARY GUIDE: Pharmaceutical Sales & Marketing

Administrative Policy and Procedure Manual. Code of Conduct Effective Date: 1/2005 Scope: Organizationwide Page 1 of 9

Professional Standards and Guidelines

3. HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION

Guidance Document Questions & Answers (Q&As) on the MedTech Europe Code of Ethical Business Practice

Marshall University Joan C. Edwards School of Medicine Conflict of Interest Policy. Introduction

CONDUCTING BUSINESS WITH CVS HEALTH

LIBRARY GUIDE: Medical Device Sales & Marketing

University of Miami Miller School of Medicine

Summary. ViiV Healthcare Compliance Program U.S. Operations

Law Department Policy No. L-1 Title:

(2) The neurological surgeon shall not participate in any activity, which is not in the best interest of the patient.

Fundraising Policies. April APPROVED BY UHKF BOARD: June 4 th, 2013

Managing Medicines Access Programs. Guiding principles for the governance of Medicines Access Programs in Australian hospitals

Brief Summary of the National Physician Payment Transparency Program: Open Payments Physician Payment Sunshine Act

DRAFT Code of Ethics. Approved by Council <date>

History and Principles of Good Clinical Practice

Guide to Advertising Compliance

Oversight of Clinical Trials in Europe - Member State perspective. Gunnar Danielsson Senior Expert Pharmaceutical Inspector

Good Clinical Practice 101: An Introduction

The Chairman s Message on Health Care Compliance

Conduct of clinical Trials Communication of

Gilead Transparency Reporting Methodological Note

Code of Ethics Approved by Council April 9, 2016

Conflict of Interest Policy

The Danish Ethical Rules for. Promotion of Medicinal Products. towards Healthcare Professionals

CODE OF ETHICS OF THE PHILIPPINE MEDICAL ASSOCIATION

May a company designate any of this information as trade secret?

I. INTRODUCTION DEFINITIONS AND GENERAL PRINCIPLE

EFPIA CODE ON THE PROMOTION OF PRESCRIPTION-ONLY MEDICINES TO, AND INTERACTIONS WITH, HEALTHCARE PROFESSIONALS. Adopted by EFPIA *

EFPIA HCP/HCO DISCLOSURE CODE

Novartis Methodological Note

Adventist HealthCare, Inc.

CODE ON THE PROMOTION OF PRESCRIPTION ONLY MEDICINES TO, AND INTERACTIONS WITH HEALTHCARE PROFESSIONALS

Yale University Open Data Access (YODA) Project Procedures to Guide External Investigator Access to Clinical Trial Data Last Updated August 2015

GOVERNMENT OF THE DISTRICT OF COLUMBIA Department of Health

GUIDELINES FOR MUSEUMS ON DEVELOPING AND MANAGING BUSINESS SUPPORT Approved, November 2001, AAM Board of Directors

Corporate Code of Conduct

Conscientious Collaboration: A Proactive Approach to Ensuring Ethical Interactions with Healthcare Professionals

CHAPTER FIVE ETHICS AND MEDICAL RESEARCH

Novartis Pharma Principles and Practices for Professionals (NP4)

Code of Conduct. Compliance W.I.N.S Worldwide Integrity is Necessary for Success


CORNERSTONE THERAPEUTICS INC. SECOND AMENDED AND RESTATED CODE OF BUSINESS CONDUCT AND ETHICS

EFPIA HCP CODE EFPIA CODE ON THE PROMOTION OF PRESCRIPTION-ONLY MEDICINES TO, AND INTERACTIONS WITH, HEALTHCARE PROFESSIONALS

Insurance and compensation in the event of injury in Phase I clinical trials

Record keeping 3. Fees and services 4. Using, recommending, providing, or selling client-care products 4. Medication 5

Co-Pay Assistance Program for CUBICIN (daptomycin for injection) for Intravenous Use Enrollment Form

TABLE OF CONTENTS. AXA Gulf Gifts and entertainment policy V1.0 Page 1

GSK Code of Practice for promotion and customer interactions

A responsible approach to clinical trials. Bioethics in action

Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes

Transcription:

Global Policy on Interactions with Healthcare Professionals

Global Policy on Interactions with Healthcare Professionals Pfizer is committed to collaborating with physicians and other healthcare professionals, to developing new healthcare products, to educating healthcare professionals, patients, and consumers about our medicines and to sharing clinical experience with the use of our products. Our mission is to be the most valued company to patients, consumers, customers, colleagues, investors, business partners and the communities where we work and live. This ambitious mission reflects the broader role society expects Pfizer to take in improving the human condition and experience. We are committed to ensuring that our educational efforts benefit patients and consumers and that our programs and collaborations do not have, or appear to have, an undue influence on medical judgment, prescribing, or product recommendations. To this end, we are guided by our company value of Integrity, our high ethical standards and our commitment to compliance with applicable legal, regulatory and professional requirements in the countries in which we operate. Our relationships with healthcare professionals, including our interactions with physicians, nurses, pharmacists and others who administer, prescribe, purchase or recommend regulated healthcare products, must meet the highest standards of integrity and must comply with applicable laws and regulations. To that end, Pfizer has adopted this Global Policy on Interactions with Healthcare Professionals. This Global Policy governs interactions with healthcare professionals by Pfizer around the world, including marketing, medical, sales and research and development operations, with the limited exception of certain business-to-business interactions, which are defined by and must comply with other applicable Pfizer policies and guidelines. Irrespective of the type of interaction, all interactions with healthcare professionals by Pfizer around the world must comply with applicable laws, regulations, professional requirements and industry codes of conduct or practice. In the event of a conflict between this Global Policy and applicable laws, regulations, professional requirements, or industry codes of conduct or practice, the more restrictive provision applies. 2 Global Policy on Interactions with Healthcare Professionals

PRINCIPLES Primacy of the Healthcare Professional Patient/Consumer Relationship We recognize that the primary duty of practicing healthcare professionals is to their patients and to the consumers that they serve. Therefore, our relationships with healthcare professionals must support, and be consistent with, the professional and fiduciary responsibilities healthcare professionals have to their patients and to consumers. Fundamentally, our interactions with healthcare professionals must advance patient care and support ethical and compassionate practices by healthcare professionals. Corporate Citizenship Facilitating access to quality healthcare is a fundamental responsibility of governments, but, to succeed, all stakeholders (including industry, healthcare professionals and patients) must work together. We are committed to doing our part by developing new products designed to prevent, treat, alleviate, or cure disease and disease symptoms or to otherwise support health and well-being, by working with other stakeholders to make healthcare products and information available to patients, consumers, and healthcare professionals and by supporting the creation and implementation of sustainable healthcare solutions. Transparency We recognize our interactions with healthcare professionals can give rise to apparent or actual conflicts of interest. We support the disclosure of financial and other interests and relationships that may create apparent or perceived conflicts of interest in research, education or clinical practice. In addition, in our dealings with healthcare professionals employed by, or affiliated with government or regulatory authorities, care will be taken to ensure that such dealings comply with all applicable laws, regulations, professional requirements or industry codes of conduct or practice. 3 Global Policy on Interactions with Healthcare Professionals

GLOBAL STANDARDS Medical Information Communications Pfizer s Medical Information Departments are designed to respond to inquiries from healthcare professionals and others about the use of our products. In providing this information about our products, we strive to ensure that such communications are accurate, substantiated, scientifically rigorous and consistent with applicable legal and regulatory standards. Promotional Activities We promote our products to healthcare professionals by providing substantiated information about the usage, safety, effectiveness and other aspects of the profile of our products. When promoting our prescription medicines, we provide information on the medicine s benefits as well as risks. Our promotional activities with healthcare professionals must help them diagnose, treat or prevent disease or alleviate the symptoms or improve the health or well-being of the patients or consumers that they serve. In addition, our promotional materials must be accurate, substantiated, scientifically rigorous and consistent with applicable legal and regulatory standards. When describing the uses, effectiveness, safety and other aspects of our products, Pfizer colleagues, retained healthcare professionals, and other third parties working on Pfizer s behalf must take care to avoid promoting, directly or indirectly, any use that Pfizer is not permitted to promote based on applicable local laws and regulations or agreements with government agencies. 4 Global Policy on Interactions with Healthcare Professionals 4

Disease Awareness Communications and Consumer Advertising Disease awareness communications and direct-to-consumer product advertising are designed to help patients and consumers make informed choices about their healthcare options. All of our product communications and advertising must be informative, accurate, substantiated, appropriately scientifically rigorous and consistent with applicable legal and regulatory standards. Privacy of Health Information We recognize that an individual s health information deserves to be treated with respect and sensitivity and that an individual s privacy must be protected. Pfizer generally does not obtain health data unless we have individual consent to obtain and use the information (as in the context of clinical trials) or unless the personal data is de-identified or aggregated so that Pfizer is unable to identify any individual s information from such data. In some instances, Pfizer may obtain identifiable health information without individual consent, but only as permitted by law, for example, in connection with important public health objectives (as in the collection of information on adverse events) or further research (for epidemiological research using healthcare databases). Pfizer requires that personal data in its care be protected appropriately, in compliance with applicable data privacy laws and regulations. 5 Global Policy on Interactions with Healthcare Professionals 5

Product Samples Samples of Pfizer products may be provided to healthcare professionals and, with respect to Pfizer non-prescription products, to consumers, in accordance with applicable laws. In markets where permitted, free samples of Pfizer products are provided to healthcare professionals for distribution to their patients. In addition, where permitted, free samples of Pfizer non-prescription products may be provided to consumers or healthcare professionals for their own use. In all instances, Pfizer product samples are provided so that patients, their healthcare professionals, and/or consumers can become familiar with the products. Product samples may not be offered or given to solicit or reward prescribing or recommending practices. Samples may not be used as gifts and may not be sold, purchased, traded or offered for sale, purchase or trade. Samples of prescription products may not be provided to healthcare professionals for their personal use or for any purpose other than free distribution to patients. Pfizer businesses providing samples must track and maintain records on all samples distributed. 6 Global Policy on Interactions with Healthcare Professionals

Support for Third Party Medical Meetings and Conferences Pfizer provides funding to third party organizations to support medical education and medical conferences. The main purpose of medical congresses, conferences, symposia and similar programs supported by Pfizer must be scientific exchange and/or medical education. Such third party conferences must be held in an appropriate venue that is conducive to the main purpose of the meeting. Hospitality offered in connection with the event must be appropriate and will not include Pfizer support or organization of entertainment (e.g., sporting or leisure) events. In no instance will Pfizer provide financial support in a manner that is inconsistent with applicable law or regulation or as an inducement for a healthcare professional to use, prescribe, purchase or recommend a Pfizer product or to influence the outcome of a clinical trial. Pfizer sponsorship of non-u.s. healthcare professional attendance at third party medical conferences or similar meetings is limited to support for travel, meals, accommodation and registration. In addition, Pfizer will not provide financial support for attendance by spouses or guests (unless qualified in their own right to attend). Pfizer-Hosted Educational and/or Promotional Meetings Pfizer-hosted educational and promotional meetings are designed to educate healthcare professionals about our products. All such meetings must be focused on education. Hospitality offered in connection with such meetings must be appropriate and will not include Pfizer-sponsored entertainment (e.g., sporting or leisure) events. Meetings should be held in appropriate venues conducive to the main purpose of the meetings and, where practical, near where the majority of the attendees live or work. In addition, Pfizer will not provide financial support for attendance by spouses or guests (unless qualified in their own right to attend). In no instance will Pfizer provide financial support as an inducement for a healthcare professional to use, prescribe, purchase or recommend a Pfizer product or to influence the outcome of a clinical trial. 7 Global Policy on Interactions with Healthcare Professionals

Consultant Meetings and Use of Healthcare Professional Consultants Qualified healthcare professionals may be hired as consultants to provide bona fide services, such as assisting in the development of products or product claims, participating in clinical trials or other research, speaking at presentations or conferences or training Pfizer colleagues. Payments to healthcare professionals for such services may not exceed the fair market value of the services provided. The venue and circumstances of any consultant meeting must be conducive to the consulting services. Activities related to the consulting services must be the primary focus of the meeting. Pfizer will only pay for the reasonable expenses (e.g., travel, meals, accommodation and registration) incurred by a consultant who attends a scientific conference or third party meeting in a professional capacity related to, or on behalf of, Pfizer. In no instance will Pfizer retain any healthcare professional, regardless of qualification, as an inducement for such healthcare professional to use, prescribe, purchase or recommend a Pfizer product or to influence the outcome of a clinical trial. Pfizer is committed to ensuring that its relationships with healthcare professionals are appropriately reviewed to ensure compliance with Pfizer policies and applicable laws. Practice-related and Other Items In markets where permitted, non-cash items related to the practice of medicine may be provided free of charge to healthcare professionals provided such items are not of significant value. In addition, an inexpensive item may be given on an occasional basis, if allowed by local law and industry practice, as part of customary interactions with a healthcare professional. In each case, Pfizer colleagues may not offer healthcare professionals any item of significant value or any item as an inducement for such healthcare professional to use, prescribe, purchase or recommend a Pfizer product or to influence the outcome of a clinical trial. 8 Global Policy on Interactions with Healthcare Professionals 8

Educational Grants Pfizer provides educational grants to support bona fide independent educational programs. Pfizer supports these programs to facilitate life-long learning by healthcare professionals, ultimately to enhance patient care. Requests for Pfizer funding are reviewed based on their merits and in accordance with all applicable laws, regulations, professional requirements and industry codes of conduct or practice. Such funding may not be used to influence or reward the recipient for present, past or future use or support of Pfizer products or to influence the outcome of clinical trials. In addition to complying with local laws, independent medical education programs must contain scientifically rigorous content and disclose the fact that Pfizer is providing financial support. Charitable Contributions Pfizer provides charitable contributions in order to support public interest activities of recognized charities and third party organizations. Requests for Pfizer funding are reviewed based on their merits and in accordance with all applicable laws, regulations, professional requirements and industry codes of conduct or practice. Such funding may not be used to influence or reward the recipient for present, past or future use or support of Pfizer products or to influence the outcome of clinical trials. 9 Global Policy on Interactions with Healthcare Professionals

Research Grants As a research based pharmaceutical manufacturer focused on health, Pfizer supports a broad range of research endeavors. We provide research grants to support scientifically compelling investigations approved by Pfizer s Medical or Research and Development groups. Requests for Pfizer funding are reviewed based on their merits and in accordance with all applicable laws, regulations, professional requirements and industry codes of conduct or practice. Such funding may not be used to influence or reward the recipient for present, past or future use or support of Pfizer products or to influence the outcome of clinical trials. Ethical Research All sponsored and supported research must be ethical in its design and implementation. We require that our sponsored clinical research conform to well-accepted international standards, such as the Good Clinical Practice (GCP) guidelines of the International Conference of Harmonization, the Nuremburg Code, the Belmont Report and relevant national and local standards (e.g., the U.S. Pharmaceutical Research Manufacturers Association (PhRMA) Principles on the Conduct and Communication of Clinical Trial Results). All clinical research protocols must be reviewed and approved by local Institutional Review Boards or Ethics Committees, except where exempted by law, and must comply with Pfizer s standards for clinical research and publications, as described in our policy on Global Clinical Trial Standards (posted at www.pfizer.com/research/ research_clinical_trials/policies_positions_casestudies.jsp). Disclosure of Clinical Trial Information All results of Pfizer-sponsored interventional clinical trials evaluating the safety and/or efficacy of a Pfizer drug, device, or biologic product are disclosed in a publicly available database. In addition, Pfizer discloses basic information about such Pfizer-sponsored studies when each trial begins. This information will be available in a public clinical trials registry. Further information about Pfizer s commitment to the disclosure of clinical trial information is available at: www.pfizer.com/research/research_clinical_trials/trial_ results_research_progress.jsp. 10 Global Policy on Interactions with Healthcare Professionals

This Global Policy on Interactions with Healthcare Professionals reflects our commitment to operating responsibly, ethically and with integrity in our business endeavors; to focusing on improving patient care and quality of life for consumers in the communities in which we operate; and to ensuring our business activities support the best practice of medicine. By establishing and following this Global Policy, we strive to fulfill those responsibilities.